Anaplastic Multiple Myeloma: An Aggressive Variant With a Poor Response to Novel Therapies

Clin Lymphoma Myeloma Leuk. 2016 Sep;16(9):e129-e131. doi: 10.1016/j.clml.2016.06.008. Epub 2016 Jun 8.

Authors

Nischala Ammannagari¹, Kimberly Celotto¹, Vishala Neppalli², Kelvin Lee¹, Sarah A Holstein³

Affiliations

¹ Department of Medicine, Roswell Park Cancer Institute, Buffalo, NY.
² Department of Pathology, Roswell Park Cancer Institute, Buffalo, NY.
³ Department of Medicine, Roswell Park Cancer Institute, Buffalo, NY. Electronic address: sarah.holstein@roswellpark.org.

PMID: 27375159
DOI: 10.1016/j.clml.2016.06.008

No abstract available

Keywords: AMM; Central nervous system involvement; Extramedullary myeloma; Immunomodulatory drug; Proteasome inhibitor.

Publication types

Case Reports

MeSH terms

Adult
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
Female
Humans
Middle Aged
Multiple Myeloma / classification
Multiple Myeloma / diagnosis
Multiple Myeloma / pathology*
Multiple Myeloma / therapy*
Neoplasm Invasiveness
Prognosis
Therapies, Investigational* / methods
Treatment Failure